The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer
Author:
Open Access
- 1 July 2008
- journal article
- Published by Taylor & Francis in Biologics: Targets and Therapy
- Vol. 2 (4) , 725-732
Abstract
The target of arachidonic acid pathway is a new anticancer strategy for human prostate cancer Masahide Matsuyama, Rikio YoshimuraDepartment of Urology, Osaka City University Graduate School of Medicine, Osaka, Japan Recent epidemiological studies and animal experiments have demonstrated that nonsteroidal anti-inflammatory drugs (NSAIDs) reduce the incidence of colorectal carcinoma. Cyclooxygenase (COX) is the principal target of NSAIDs. COX is the first oxidase in the process of prostaglandin production from arachidonic acid. COX enzyme may be involved in the initiation and/or the promotion of carcinogenesis due to NSAIDs inhibition of COX. Lipoxygenase (LOX) is also an initial enzyme in the pathway for producing leukotrienes from arachidonic acid. Similar to COX, LOX enzyme may also be involved in the initiation and/or promotion of carcinogenesis. Peroxisome proliferator activator-receptor (PPAR)-γ is a ligand-activated transcriptional factor belonging to the steroid receptor superfamily. PPAR-γ plays a role in both adipocyte differentiation and carcinogenesis. PPAR-γ is one target for cell growth modulation of NSAIDs. In this review, we report the expression of COX-2, LOX and PPAR-γ in human prostate cancer tissues as well as the effects of COX-2 and LOX inhibitors and PPAR-γ ligand.Keywords: cyclooxygenase, lipoxygenase, peroxisome proliferator activator-receptor-γ, prostate cancerKeywords
This publication has 39 references indexed in Scilit:
- Anticancer effects of licofelone (ML-3000) in prostate cancer cells.2007
- Overexpression of cysteinyl LT1 receptor in prostate cancer and CysLT1R antagonist inhibits prostate cancer cell growth through apoptosisOncology Reports, 2007
- New COX-2/5-LOX Inhibitors: Apoptosis-Inducing Agents Potentially Useful in Prostate Cancer ChemotherapyJournal of Medicinal Chemistry, 2004
- The effects of cyclooxygenase-2 inhibitors on urological cancer cells.International Journal of Molecular Medicine, 2004
- Expression of Lipoxygenase in Human Bladder Carcinoma and Growth Inhibition by Its InhibitorsJournal of Urology, 2003
- Suppression of N-methyl-N-nitrosourea/testosterone-induced rat prostate cancer growth by celecoxib: effects on cyclooxygenase-2, cell cycle regulation, and apoptosis mechanism(s).2003
- Nonapoptotic cell death associated with S-phase arrest of prostate cancer cells via the peroxisome proliferator-activated receptor gamma ligand, 15-deoxy-delta12,14-prostaglandin J2.2000
- Identification, Characterization, and Tissue Distribution of Human Peroxisome Proliferator-activated Receptor (PPAR) Isoforms PPARγ2 versus PPARγ1 and Activation with Retinoid X Receptor Agonists and AntagonistsJournal of Biological Chemistry, 1997
- Expression of cyclooxygenase-1 and -2 in human colorectal cancer.1995
- Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferatorsNature, 1990